After dynamically changing March and April operations in response to the COVID-19 pandemic, it does not appear that our fellows will need to be reassigned to other services allowing us to return to fairly standard operations starting May 1. Although fellows will be on inpatient and outpatient clinics and research, we are still asking attendings to ensure that they do not pre-round on inpatient so as to continue to limit patient contacts for the time being. We will continue to hold our educational conferences virtually through the end of the academic year. We encourage you to listen and participate. One of the benefits of these virtual meetings is that it has made conferences more accessible to everyone. I want to take this time to commend our fellows, faculty, and staff for their flexibility during the pandemic.
After several years of excellent work Liz Kessler, MD, has stepped down as the site director at UCH. In her time as site director Dr. Kessler worked hard to improve the inpatient and outpatient experience for our fellows. We are happy to name Lindsey Davis, MD, will pick up where Dr. Kessler left off as the new UCH site director and are delighted to welcome her onboard. Please be sure to direct questions about UCH Medical Oncology rotations to Dr. Davis moving forward.
While we were looking forward to our fellowship graduation barbecue in June, the in person celebration has been cancelled and graduation will now be held virtually. More details will be forthcoming as we decide how we can best celebrate our graduates virtually. We do hope to celebrate with our 2020 graduates in person in the future! As we say goodbye to one group of fellows we are also preparing to welcome our incoming fellows! Despite the impacts of COVID-19, we are still planning on welcoming our first year fellows on July 1. We have set aside July 2 and July 3 for orientation with the first day of clinical rotations beginning July 4, the current first year fellows will continue their rotations through July 4. As a reminder, we will have five fellows per year starting 2020-2021.
In other news, there have been several publications from our current fellows since our last update. We encourage you to check them out!
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020;21:e191-e204. PMID 31859066
Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PMID 32351892
Hararah MK, Stokes WA, Oweida A, Patil T, Amini A, Goddard J, Bowles DW, Karam SD. Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope. 2020 Feb;130(2):405-412. doi: 10.1002/lary.27994. Epub 2019 Apr 12. PMID 30977524
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 Apr;10(4):536-551. Epub 2020 Jan 23. PMID 31974170
Kagihara JA, Andress M, Diamond JR. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Rev Precis Med Drug Dev. 2020;5(2):59-65. Epub 2020 Feb 20. PMID 32190733